Cerus Reports Q4 Revenue Growth, INTERCEPT Fibrinogen Complex Drives Growth, Faces Financial Challenges

Cerus Corporation (CERS) reports a 14% YoY increase in Q4 product revenue, driven by strong performance in its blood safety products, with INTERCEPT Fibrinogen Complex revenue up 40% in Q4 and 80% for the full fiscal year. Despite revenue growth, Cerus faces financial challenges, including a negative operating margin and a distressing Altman Z-Score. The company's stock is traded on the NASDAQ exchange with a market capitalization of approximately $395.7 million.